AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

The Ischemic Cliff: A Primary Restricted Cubic Spline Meta-Analysis Defining the J-Curve of Continuous Diastolic Blood Pressure in Intensive Hypertension Control

By Yathindra MR, shabrawi MN, Alupei E et al.

Background: The SPRINT trial established systolic blood pressure (SBP) <120 mmHg as the intensive treatment target, yet current guidelines provide no diastolic blood pressure (DBP) floor, creating a coronary perfusion blind spot. Diastolic hypoperfusion during intensive SBP lowering may precipitate myocardial ischemia, particularly in patients with coronary artery disease (CAD). We conducted a restricted cubic spline (RCS) meta-analysis to define the DBP J-curve and identify the "ischemic cliff" threshold. Methods: We systematically searched PubMed, MEDLINE, EMBASE, and the Cochrane Library from inception to March 2026 to identify relevant studies and performed a primary RCS meta-analysis of post-hoc DBP-stratified data from five trials: SPRINT, ACCORD-BP, ONTARGET, INVEST and Framingham Heart Study totaling 67,657 participants. Major adverse cardiovascular events (MACE) were modeled as a continuous function of achieved DBP using RCS with knots at 60, 70, and 80 mmHg. Hazard ratios (HR) were pooled using random-effects models, with subgroup analyses stratified by CAD status. Results: The pooled analysis revealed a J-shaped relationship with a nadir DBP of 79 mmHg (95% CI: 76-82 mmHg). Risk increased sharply below 65 mmHg—the "ischemic cliff"—with pooled HR of 2.06 (95% CI: 1.76-2.40) for DBP <60 mmHg compared to the nadir. CAD patients demonstrated a higher optimal DBP (INVEST nadir: 84 mmHg), while non-diabetic hypertensive patients showed lower nadirs (SPRINT: 70 mmHg; ACCORD-BP: 72 mmHg). Below 65 mmHg, myocardial infarction risk exceeded stroke risk across all trials. The J-curve persisted after propensity-score matching for baseline characteristics and intensive versus standard treatment assignment. Conclusions: This primary RCS meta-analysis identifies a critical guideline gap: no DBP safety threshold exists in current intensive BP management protocols. We propose a DBP floor of ≥65 mmHg to prevent coronary hypoperfusion during intensive SBP lowering. Clinicians should monitor achieved DBP closely, particularly in elderly patients and those with established CAD, where diastolic hypoperfusion may negate the benefits of intensive SBP control.

doi.org/10.1161/circ.154.suppl_1.5771Interventions

AgingResearch.News